Abstract
miR-101 is an outstanding tumor suppressor in various cancers, while its role in pancreatic cancer (PC) is still unknown. The aim of this study was to investigate the role of miR-101 in epithelial-to-mesenchymal transition (EMT) and its clinical relevance in PC. Our data showed that the miR-101 expression was significantly decreased in human PC tissues, compared to non-tumor counterparts (p<0.05), which was reversely correlated to clinical characteristics, including lymph node metastasis, more venous infiltration, higher expression of CA19-9 and TNM stage (p<0.05). Low miR-101 expression was also confirmed to be associated with a poorer overall survival rate in PC patients (p<0.05). We identified high-mobility group AT-hook 2 (HMGA2) gene as a putative target of miR-101 in PC by bioinformatics analysis, dual luciferase activity and western blot assay, and found that miR-101 could specifically target the HMGA2 3’-untranslated region (3’-UTR) (p<0.05). Knockdown of HMGA2 reversed EMT resembling that of miR-101 over-expression. An inverse correlation between miR-101 and HMGA2 was observed in patients with PC (p<0.05). Taken together, our findings speculated that miR-101 might act as an inhibiting factor in EMT process in PC and up-regulation of miR-101 might be considered as a potentially key molecular treatment strategy for PC patients.
Keywords: Epithelial-to-mesenchymal transition, HMGA2, miR-101, pancreatic cancer.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:miRNA-101 Suppresses Epithelial-to-mesenchymal Transition by Targeting HMGA2 in Pancreatic Cancer Cells
Volume: 16 Issue: 4
Author(s): Yixing Guo, Xiaogeng Deng, Qiaoming Zhi, Jin Zhou, Jin Tang, Lexiang Zeng, Jiemin Deng, Zhixi Li, Daiwei Wan, Wenli Jiang, Jiajia Zhou, Jie Zhang, Yaohao Wu, Chenglong Shen, Songbing He, Ronglin Qiu and Wen Gu
Affiliation:
Keywords: Epithelial-to-mesenchymal transition, HMGA2, miR-101, pancreatic cancer.
Abstract: miR-101 is an outstanding tumor suppressor in various cancers, while its role in pancreatic cancer (PC) is still unknown. The aim of this study was to investigate the role of miR-101 in epithelial-to-mesenchymal transition (EMT) and its clinical relevance in PC. Our data showed that the miR-101 expression was significantly decreased in human PC tissues, compared to non-tumor counterparts (p<0.05), which was reversely correlated to clinical characteristics, including lymph node metastasis, more venous infiltration, higher expression of CA19-9 and TNM stage (p<0.05). Low miR-101 expression was also confirmed to be associated with a poorer overall survival rate in PC patients (p<0.05). We identified high-mobility group AT-hook 2 (HMGA2) gene as a putative target of miR-101 in PC by bioinformatics analysis, dual luciferase activity and western blot assay, and found that miR-101 could specifically target the HMGA2 3’-untranslated region (3’-UTR) (p<0.05). Knockdown of HMGA2 reversed EMT resembling that of miR-101 over-expression. An inverse correlation between miR-101 and HMGA2 was observed in patients with PC (p<0.05). Taken together, our findings speculated that miR-101 might act as an inhibiting factor in EMT process in PC and up-regulation of miR-101 might be considered as a potentially key molecular treatment strategy for PC patients.
Export Options
About this article
Cite this article as:
Guo Yixing, Deng Xiaogeng, Zhi Qiaoming, Zhou Jin, Tang Jin, Zeng Lexiang, Deng Jiemin, Li Zhixi, Wan Daiwei, Jiang Wenli, Zhou Jiajia, Zhang Jie, Wu Yaohao, Shen Chenglong, He Songbing, Qiu Ronglin and Gu Wen, miRNA-101 Suppresses Epithelial-to-mesenchymal Transition by Targeting HMGA2 in Pancreatic Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1871520615666150507122142
DOI https://dx.doi.org/10.2174/1871520615666150507122142 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism Tribulus arabicus and Tribulus macropterus are Comparable to Tribulus terrestris: An Antioxidant Assessment
Current Bioactive Compounds Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEXDC<sup>®</sup>) in the Palliative Treatment of Pancreatic Cancer
Current Medicinal Chemistry Bioactive Food Components as Dietary Intervention for Cystic Fibrosis
Current Drug Targets Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Polysaccharide-Based Materials Associated with or Coordinated to Gold Nanoparticles: Synthesis and Medical Application
Current Medicinal Chemistry Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Current HIV Research Immune System, Cell Senescence, Aging and Longevity - Inflamm-Aging Reappraised
Current Pharmaceutical Design Recent Insights on the Pro-Apoptotic Phenotype Elicited by Presenilin 2 and its Caspase and Presenilinase-Derived Fragments
Current Alzheimer Research Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Circulating Nucleic Acids as a Potential Source for Cancer Biomarkers
Current Molecular Medicine Integrated Genomic and Pharmacological Approaches to Identify Synthetic Lethal Genes as Cancer Therapeutic Targets
Current Molecular Medicine Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Impacts of Particulate Air Pollution on Asthma: Current Understanding and Future Perspectives
Recent Patents on Inflammation & Allergy Drug Discovery New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Current Cancer Therapy Reviews Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton’s Tyrosine Kinase Inhibition
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Erectile Dysfunction an Example of Abnormal Endothelial Function?
Current Vascular Pharmacology Adjuvant Hormonal Therapy in Women with Early-stage Breast Cancer
Medicinal Chemistry CCR2 Antagonists
Current Topics in Medicinal Chemistry Effect of Formulations of Nanosized Quercetin Liposomes on COX-2 and NF-kB in MCF-10A Cells
Pharmaceutical Nanotechnology